LyticGen files patent for CRISPR-enhanced phage therapy for MRSA

LyticGen Pharmaceuticals filed a provisional patent for VDX-10, a CRISPR-engineered bacteriophage designed to target MRSA and other Staphylococcus aureus infections. The Dallas biotech is aiming for an FDA IND filing in 2027 as it seeks to advance a new approach to drug-resistant infections.

Why it matters: - MRSA still causes more than 80,000 serious infections and over 10,000 deaths each year in the U.S. - Standard antibiotics, including vancomycin, still leave MRSA bacteremia with a 30-day mortality rate of 15% to 50%. - LyticGen is trying to build a non-antibiotic treatment option for a pathogen that has not seen a new FDA-approved antibiotic class in more than 20 years.

What happened: - LyticGen Pharmaceuticals filed a provisional patent application with the U.S. Patent and Trademark Office on June 4, 2026, under Application No. 64/082,295. - The filing covers the company’s CRISPR-enhanced bacteriophage platform and lead candidate, VDX-10. - The company disclosed the filing on June 12, 2026.

The details: - The patent application covers a two-stage phage engineering platform that includes progenitor phage enrichment and selection, CRISPR/Cas9-mediated genomic enhancement, and genetically modified bacteriophage compositions and therapeutic methods. - LyticGen says the first stage screens candidate bacteriophages in controlled isolation chambers to identify the progenitor with the highest lytic activity against target S. aureus strains. - The second stage uses CRISPR/Cas9 editing to insert gene sequences designed to accelerate replication, widen host range across clinical S. aureus isolates, and disable bacterial anti-phage defenses. - VDX-10 is designed to target Staphylococcus aureus, including methicillin-resistant S. aureus, or MRSA. - The patent claims also cover pharmaceutical formulations and adaptive treatment methods that include microbiological monitoring and re-dosing protocols. - The provisional filing establishes a priority date of June 4, 2026. - A non-provisional patent application is due in June 2027. - LyticGen is a Dallas-based development-stage biopharmaceutical company focused on antibiotic-resistant infections. - The company’s lead candidate remains patent-pending. - VDX-10 is being developed for MRSA bacteremia and ventilator-associated pneumonia.

Between the lines: - The patent filing gives LyticGen an early intellectual-property stake while the company moves a preclinical program toward human testing. - The CRISPR-enhanced approach is meant to address known limits of natural phage therapy, including narrow host range, bacterial immune defenses and variable clinical performance. - LyticGen’s pitch is that bacteriophages can attack bacteria through a mechanism different from antibiotics, which could matter as resistance limits current treatment options. - The company is also signaling a commercial strategy, with MRSA treatment drugs in a market the company cites as roughly $4 billion in 2024 and potentially $5 billion to $7 billion by 2033. - LyticGen cited independent market research projecting the bacteriophage therapy market to reach $1 billion by 2030.

What's next: - LyticGen plans to keep advancing VDX-10 through preclinical development. - The company is targeting an Investigational New Drug filing with the FDA in 2027. - LyticGen is pursuing Qualified Infectious Disease Product designation and FDA Fast Track designation for VDX-10. - MRSA is a named QIDP-qualifying pathogen under the GAIN Act framework. - VDX-10 has not received FDA approval and is not available for commercial sale.